Related Experiment Video
Updated: Jun 13, 2026
10:39
Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding
Published on: August 30, 2024
Galectin-3 in cardiac remodeling and heart failure
Rudolf A de Boer1, Lili Yu, Dirk J van Veldhuisen
1Department of Cardiology, Division of Experimental Cardiology, University Medical Center Groningen, PO Box 30.001, Groningen, 9700 RB, The Netherlands. r.a.de.boer@thorax.umcg.nl
Current Heart Failure Reports
|April 29, 2010
Summary
Galectin-3, a protein involved in heart failure, is elevated in decompensated cases. This finding suggests galectin-3 may serve as a valuable biomarker for heart failure diagnosis and treatment.
Area of Science:
- Biochemistry
- Cardiology
- Immunology
Background:
- Galectin-3 is an animal lectin that binds beta-galactosides.
- Emerging evidence links galectin-3 to the pathophysiology of heart failure.
- Galectin-3 expression is elevated in decompensated heart failure models.
Purpose of the Study:
- To investigate the role of galectin-3 in heart failure.
- To evaluate galectin-3 as a potential biomarker for heart failure.
- To explore galectin-3's association with cardiac remodeling.
Main Methods:
- Animal models of heart failure were utilized.
- Galectin-3 expression levels were compared between compensated and decompensated heart failure.
- Fibroblast and macrophage activation were assessed.
Main Results:
- Galectin-3 was significantly upregulated in decompensated heart failure compared to compensated heart failure.
- Increased galectin-3 levels correlated with fibroblast and macrophage activation.
- Initial clinical data suggest galectin-3 offers added value over B-type natriuretic peptide.
Conclusions:
- Galectin-3 is implicated in the cardiac remodeling associated with heart failure.
- Galectin-3 shows promise as a novel biomarker for decompensated heart failure.
- Further research into galectin-3 biology and anti-galectin-3 therapies is warranted.
Related Concept Videos
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
01:26Heart Failure III: Clinical Manifestations
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...